OBJECTIVE: We investigated the hypothesis that rimonabant, a cannabinoid antagonist/inverse agonist, would increase anxiety in healthy subjects during a simulation of the public speaking test. METHODS: Participants were randomly allocated to receive oral placebo or 90 mg rimonabant in a double-blind design. Subjective effects were measured by Visual Analogue Mood Scale. Physiological parameters, namely arterial blood pressure and heart rate, also were monitored. RESULTS: Twelve participants received oral placebo and 12 received 90 mg rimonabant. Rimonabant increased self-reported anxiety levels during the anticipatory speech and performance phase compared with placebo. Interestingly, rimonabant did not modulate anxiety prestress and was not associated with sedation, cognitive impairment, discomfort, or blood pressure changes. CONCLUSIONS: Cannabinoid-1 antagonism magnifies the responses to an anxiogenic stimulus without interfering with the prestress phase. These data suggest that the endocannabinoid system may work on-demand to counteract the consequences of anxiogenic stimuli in healthy humans.
RCT Entities:
OBJECTIVE: We investigated the hypothesis that rimonabant, a cannabinoid antagonist/inverse agonist, would increase anxiety in healthy subjects during a simulation of the public speaking test. METHODS:Participants were randomly allocated to receive oral placebo or 90 mg rimonabant in a double-blind design. Subjective effects were measured by Visual Analogue Mood Scale. Physiological parameters, namely arterial blood pressure and heart rate, also were monitored. RESULTS: Twelve participants received oral placebo and 12 received 90 mg rimonabant. Rimonabant increased self-reported anxiety levels during the anticipatory speech and performance phase compared with placebo. Interestingly, rimonabant did not modulate anxiety prestress and was not associated with sedation, cognitive impairment, discomfort, or blood pressure changes. CONCLUSIONS:Cannabinoid-1 antagonism magnifies the responses to an anxiogenic stimulus without interfering with the prestress phase. These data suggest that the endocannabinoid system may work on-demand to counteract the consequences of anxiogenic stimuli in healthy humans.
Authors: Jaime E C Hallak; José Alexandre S Crippa; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio Egidio Nardi; Flávio Kapczinski Journal: Braz J Psychiatry Date: 2010-03 Impact factor: 2.697
Authors: Roger S McIntyre; Mohammad Alsuwaidan; Benjamin I Goldstein; Valerie H Taylor; Ayal Schaffer; Serge Beaulieu; David E Kemp Journal: Ann Clin Psychiatry Date: 2012-02 Impact factor: 1.567
Authors: J Haller; I Barna; B Barsvari; K Gyimesi Pelczer; S Yasar; L V Panlilio; S Goldberg Journal: Psychopharmacology (Berl) Date: 2009-03-04 Impact factor: 4.530
Authors: Don Wei; DaYeon Lee; Conor D Cox; Carley A Karsten; Olga Peñagarikano; Daniel H Geschwind; Christine M Gall; Daniele Piomelli Journal: Proc Natl Acad Sci U S A Date: 2015-10-26 Impact factor: 11.205